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Summary
The Lee Silverman Voice Treatment (LSVT) has been shown to be highly effective in treating the speech disorder in Parkinson’s
Disease (PD). However, patient access to this treatment remains limited in Australia, due to availability of speech pathologists,
patient mobility and distance issues. We have investigated the feasibility and effectiveness of an Internet-based telerehabilitation
application (eREHAB) for the delivery of the LSVT to persons with PD and disordered speech. Ten participants with PD and
dysarthria were treated online with the LSVT for a total of 16 sessions. There were significant improvements in sound pressure
levels for vowel prolongation, reading and conversational monologue (Po0.01), pitch range (Po0.05) and in perceptual
features of pitch and loudness variability, loudness level (Po0.01) and breathiness (Po0.05). A participant satisfaction
questionnaire indicated that 70% of participants expressed overall satisfaction with the online treatment. Telerehabilitation was
feasible and effective in delivering the LSVT to people with PD.
Introduction
Parkinson’s Disease (PD) is a progressive neurological
disorder associated with significant physical,
psychological and communicative impairments. One of
the most distressing symptoms of PD is a speech disorder
known as hypokinetic dysarthria which occurs in more
than 75% of patients with PD, with the incidence and
severity of the disorder increasing with disease
progression.1,2 The speech disturbance is characterised by
monotony of pitch and loudness, imprecise articulation,
reduced volume, and a breathy and hoarse vocal quality.1,3
As a consequence of the speech impairment, the social,
psychological and economic well-being of the person with
PD are often seriously affected, such that the individual
becomes increasingly isolated within his/her own family
and the community at large.2,4
To date, the most effective treatment for the speech
disturbance associated with PD is the Lee Silverman Voice
Treatment (LSVT ) programme developed by Ramig and
colleagues.5 This treatment has been shown to be effective
in improving the speech and voice in 90% of persons with
idiopathic PD and hypokinetic dysarthria, with the
positive effects of this intervention being documented for
up to two years post therapy.6 The treatment is a
structured programme delivered intensively in 16 sessions
over four weeks. The aim is to increase vocal volume and
physiological effort to produce a loud voice. Significant
improvements in vocal parameters (volume, pitch and
loudness variability, and vocal quality) articulation, rate of
speech, intonation, speech intelligibility and functional
communication have occurred as a result of this
treatment.7
Despite the existence of this effective speech treatment,
access to the LSVT for people with PD remains limited,
particularly in regional and rural/remote areas of Australia.
One barrier to accessing treatment is the limited
availability of certified LSVT clinicians in these
communities. There are persistent difficulties in recruiting
and retaining speech pathologists in rural and remote
settings in Australia8 and the probability of a certified
LSVT clinician working in these areas is extremely low.
Another barrier to accessing treatment relates to mobility
issues specific to this population. For many people with
PD, their movement disorder alone may preclude or
impede their attendance at a health care facility, in either
an urban or rural environment. In addition, the majority
of people with PD are elderly and frequently depend on a
spouse of similar age, or carer, to assist them. This further
complicates their access to services.
While there have been several telehealth applications
developed to assess and treat various communication
disorders,9 there do not appear to have been any online
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applications specifically designed to treat the dysarthric
speech disturbance associated with PD. The aim of the
present study was to determine the feasibility and efficacy
of an Internet-based telerehabilitation application
specifically designed to deliver the LSVT online.
Methods
Ten participants (mean age 73 years, SD 10) were recruited
to the study. They had been diagnosed with idiopathic PD
by a neurologist, and with a perceptible hypokinetic
dysarthria by a speech pathologist. The participants were 8
males and 2 females, with a mean post-onset duration of
5.7 years (range 1–14 years). The severity of dysarthria
ranged from mild to moderate-severe. Participants were
excluded from the study if they had a history of, or a co-
existing neurological disorder other than PD, a previous
history of speech disturbance prior to the present
speech deficit, respiratory and laryngeal dysfunction
unrelated to PD, or a positive history of alcohol abuse and/
or dementia.
Equipment
The telerehabilitation system (eREHAB) used to administer
the LSVT online provided videoconferencing via a
128 kbit/s Internet link. The system used two Web cameras
at the patient’s end (Figure 1), remotely controlled by the
clinician’s computer (Figure 2). A store-and-forward
facility allowed the capture of high quality (PAL
resolution) video and audio recordings for assessment and
treatment purposes, from the second Web camera. The
system’s speech processor generated real-time calibrated
sound pressure level (SPL) (dB-C) and peak frequency (Hz)
during assessment and treatment tasks. This processor, in
combination with a headset microphone worn by the
participant, delivered continuous sound level and pitch
data to the eREHAB system and then to the clinician in
real-time. A text transfer facility enabled printed stimulus
and treatment materials to be sent by the clinician to the
participant’s computer.
Procedure
The participant, wearing a headset microphone positioned
5 cm from the corner of their mouth, sat in front of the
eREHAB system and interacted with a clinician in another
room via the videoconference link. Prior to, and following
the treatment, each participant was assessed online by a
researcher not involved in the treatment. Assessment
involved measures of the average SPL of the participant’s
voice during the production of six sustained phonations of
the vowel /a/, reading of a standard passage, and during a
30–40s sample of a conversational monologue. A measure
of pitch range was determined from the difference
between the means of the participant’s highest and lowest
pitch levels achieved during six pitch glides to highest and
to lowest pitch levels, respectively, as measured by the
eREHAB speech processor.
Perceptual ratings of the participant’s reading and
conversational monologue samples from audio recordings
obtained online pre- and post-treatment were performed
by two clinicians independent of the study. These samples
were rated on a 5-point scale (1¼normal to 5¼ severe
impairment) according to seven parameters of speech and
voice: overall speech intelligibility, articulatory precision,
breathiness, hoarseness, pitch and loudness variability,
and loudness level. The pre-and post-treatment speech
samples were randomly recorded onto a CD with 30% of
the samples (3 pre- and 3 post-treatment samples) repeated
for intra-rater reliability analysis. Each clinician
independently rated the samples and was permitted to
listen to the recordings as many times as required to make
a judgement.
Intra-class correlations revealed high inter-rater
reliability (ICC¼0.75) across all 7 parameters rated with
percentage levels of agreement between the raters ranging
from 95 to 100% at 71 point on the rating scale. Intra-
rater reliability was found to be high for both rater 1
(ICC¼0.92) and rater 2 (ICC¼0.94), with both raters
achieving 100% level of agreement at 71 on the scale.
Where the ratings differed by one or more points on the
scale, these samples were re-rated in a subsequent session
where the two clinicians conferred to produce a single
consensus rating which was then used in the statistical
analyses.10
Figure 1 Equipment at the patient’s end Figure 2 Equipment at the clinician’s end
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Each participant was treated by a certified LSVT clinician
as prescribed by Ramig et al.5 for one hour per day, 4 days
per week, for 4 weeks. The treatment involved multiple
repetitions of sustained phonation, pitch glides and
functional phrases in a loud voice, as well as reading and
conversational activities. In addition to the treatment
sessions, the participant was required to complete daily
homework exercises and functional communication
assignments throughout the 4 week programme.
Following the treatment, each participant completed a 7-
item participant satisfaction questionnaire relating to the
online environment including audio and visual quality,
and overall satisfaction with the online treatment
experience.
Results
The pre- and post-treatment results for measures of SPL
and pitch range were analysed using paired t-tests to
determine treatment effects (Po0. 05). Results indicated
significant increases in SPL for sustained phonation,
reading and conversational speech for the group (Table 1).
Similarly, a significant increase in mean pitch range
(t¼2.5; P¼0.032) was identified pre (mean 157.8 Hz, SD
91.0) to post-treatment (mean 229.5 Hz, SD 88.5).
Comparisons of the perceptual ratings pre- and post-
treatment using Wilcoxon signed ranks testing revealed
significant improvements in the degree of breathiness in
the voice, loudness level, and pitch and loudness
variability pre- to post-treatment (Table 2). While
improvements in hoarseness, speech intelligibility and
articulatory precision were identified post-treatment,
these changes were not found to be significantly different
from pre-treatment ratings (Table 2).
The participant satisfaction questionnaire data revealed
that 70% of participants were more than satisfied overall
(ratings included ‘satisfied’, ‘more than satisfied’ and ‘very
satisfied’) with the online treatment; the remaining 30%
were very satisfied with the experience. With respect to
audio quality, 90% of the participants rated this aspect of
the system as adequate to excellent with 10% of
participants rating it as inadequate. The visual quality of
the system was rated as adequate or better by 70% of
participants, while 30% considered the quality to be less
than adequate.
Discussion
The results of the present study indicate that
improvements in the dysarthric speech disturbance
associated with PD can be achieved through the delivery
of the LSVT across the Internet. Significant improvements
in vocal volume in a variety of speech tasks and several
perceptual features of voice and speech were achieved.
These improvements were consistent with previously
reported outcomes for the LSVT when delivered face-to-
face. Previous studies have found post-LSVT increases in
SPL of approximately 4.6 dB for conversational
monologue, 8 dB for reading, and up to 14 dB for sustained
phonation.11,12 These increases are consistent with the
values for SPL obtained in the present study for
conversational monologue (5.5 dB), reading (7.5 dB) and
sustained phonation (10.8 dB), indicating that the primary
focus of the LSVT, increasing vocal volume, can be
achieved online.
Breathiness, a common feature of the speech disorder in
PD,3 is considered to be associated with incomplete vocal
fold adduction, reduced laryngeal muscle activation,
abnormal vocal fold tension or movement, and/or
stiffness and rigidity.13,14 Previous studies have
demonstrated significant improvements in perceptual
ratings of breathiness of the voice following LSVT15
consistent with concomitant improvements in acoustic
and physiological characteristics of laryngeal
function.5,11,12,16 The significant improvement in
perceived breathiness in the participants’ voices in the
current study post-LSVT is, therefore, consistent with
previously reported effects of the LSVT delivered
face-to-face.
Similarly, the significant improvements in perceived
loudness level and pitch and loudness variability
identified in the present study are consistent with
previously reported treatment effects of the LSVT.11 A soft
vocal volume and reduced pitch and loudness variability
are cardinal features of hypokinetic dysarthria.3 The LSVT
is specifically designed to improve the overall loudness
level and variability of the person’s voice through exercises
to improve respiratory drive, vocal fold adduction and
sub-glottal pressure. In addition, the treatment includes
exercises to lengthen and shorten the vocal folds in order
to facilitate greater variations in pitch of the voice.5
Table 1 Pre- and post-treatment SPL recordings (dB)
Task
Pre-treatment
mean (SD)
Post-treatment
mean (SD)
P-value
(t-test)
Sustained phonation 73.2 (3.1) 84.0 (3.5) 0.0001
Reading 65.1 (1.2) 72.6 (2.5) 0.0001
Monologue 64.5 (1.7) 70.0 (1.8) 0.0001
Table 2 Pre- and post-treatment perceptual ratings of speech (on
a 5 point scale)
Rating
Pre-
treatment
mean (SD)
Post-
treatment
mean (SD)
P-value
(Wilcoxon signed
ranks test)
Speech intelligibility 2.1 (0.87) 1.7 (0.94) 0.102
Articulatory precision 1.9 (0.87) 1.6 (0.96) 0.083
Breathiness 2.2 (0.63) 1.4 (0.51) 0.011
Hoarseness 1.9 (0.56) 1.6 (0.51) 0.083
Pitch variability 2.0 (0.47) 1.2 (0.42) 0.005
Loudness variability 2.3 (0.48) 1.3 (0.48) 0.008
Loudness level 2.4 (0.51) 1.4 (0.51) 0.008
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Although the results suggested a trend to improvements
in perceived speech intelligibility, articulatory precision
and the degree of hoarseness in the treatment group, the
lack of significant change pre- to post-treatment may
reflect the relatively small sample size, the predominantly
mild speech disturbances exhibited by the participants
and/or the inherent difficulties of perceptual rating. While
the small group sample size may have contributed to the
lack of significant improvements in these speech and voice
features, it is also possible that the 5-point rating scale was
insufficiently discriminating for persons with mild speech
and voice disturbances and therefore, no significant
treatment effect was determined for the group. It has also
been reported that perceptual rating of vocal quality,
such as hoarseness, is particularly difficult and thus less
reliable than expected.17 Future research involving larger
numbers of participants exhibiting a wider range of
severity of the speech disturbance may achieve different
outcomes.
Positive feedback regarding the online treatment
experience was obtained from the majority of participants
indicating that online delivery of the treatment was
acceptable. Some respondents, however, indicated that the
audio and visual quality was less than adequate. As this
application utilised an IP connection, the audio and visual
quality of the eREHAB system was at times compromised
by competing Internet traffic, which resulted in less than
ideal audio and visual quality. Despite this problem all
assessment and treatment sessions were completed by
each participant. Although using a low speed bandwidth
connection limited the performance of the current system
to some degree, the application was designed to function
in rural areas in Australia where low Internet connections
exist.
In conclusion, the results of the study demonstrate the
feasibility of an Internet-based telerehabilitation
application designed to deliver the LSVT to persons with
PD. Further research, involving larger numbers of
participants, will now be required to validate the
effectiveness of online LSVT compared to face-to-face
treatment delivery.
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